Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1116 participants.
Also called NCT04072835
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,116 participants
- Registry
-
NCT04072835
-
- Other papers using this trial's data
- Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE-303 Open-Label Study
- Self-Administered Etripamil Nasal Spray Slows Ventricular Rate in Patients With Atrial Fibrillation: A Post Hoc Analysis of the NODE-303 Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Canada, Colombia
- Registry status
- Completed
Technical summary
Registry record NCT04072835. Non-randomized; no masking; primary purpose treatment. Start 2019-09-23 (actual); primary completion 2023-01-26 (actual). Results posted on 2024-05-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
- Condition
- Paroxysmal Supraventricular Tachycardia
- Intervention (Drug)
- Etripamil NS
- Lead sponsor
- Milestone Pharmaceuticals Inc.
- Collaborator
- IQVIA Biotech
Record details
- Record id
cardio:ct-nct04072835- Content hash
da0d92ccb9d99370ebe0af185b930adcd7ba74b7eddde98550e92535f4e494ef